L'intérêt à découvert pour Oncternal Therapeutics donne aux investisseurs une idée du degré auquel les investisseurs parient sur la baisse de l'action de Oncternal Therapeutics. Les données sur l'intérêt à découvert sont mises à jour toutes les deux semaines.

Oncternal Therapeutics (NASDAQ:ONCT) Stock, Rapport sur les intérêts à découvert

Oncternal Therapeutics

Oncternal Therapeutics Inc is a clinical-stage oncology company developing first-in-class, novel therapies that target a broad spectrum of cancers with a large unmet medical need. The Company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to ROR1 (Receptor-tyrosine kinase-like Orphan Receptor 1), and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoprotein. The Company is also developing ONCT-808, a CAR-T (chimeric antigen receptor T-cells) product candidate that target ROR1, and ONCT-534, a dual-action androgen receptor inhibitor product candidate for the treatment of castration-resistant prostate and other androgen receptor-driven cancers. The Company has one operating segment in the United States.

Oncternal Therapeutics, Inc. - Common Stock

Oncternal Therapeutics Inc

After factoring in estimated closing adjustments and new non-recourse project-level debt, the Company expects its total long-term corporate capital commitment to acquire the project to be approximately $70-75 million, which the Company expects to fund with existing sources of liquidity.
The Company expects the transaction to close in the first quarter of 2025, after which its targeted contribution to fiscal year 2025 results will be communicated.

News

CWEN

Clearway Energy Enters Binding Agreement To Acquire Operational Tuolumne Wind Project From Turlock Irrigation District

Earnings

Guidance

SUPV

Grupo Supervielle Q3 Net Income AR$8.9B; Confirm 15% ROE Guidance For FY2024

The jury found that Natera engaged in a deliberate campaign to mislead cancer clinicians about Guardant Reveal – Guardant Health's tissue-free minimal residual disease (MRD) test for early-stage colorectal cancer (CRC) – in favor of Signatera&#x2122;, Natera's competing product.&nbsp;

Legal

NTRA

Guardant Health Says Jury Unanimously Rejected All Of Natera's Counterclaims And Awarded $292.5M To Company, Including $175.5M In Punitive Damages

CHCI

Comstock Holding Says Carr Workplaces Signed New 26,331 Square Foot Lease At The Hartford In Arlington, Virginia

Shares of Hims &amp; Hers Health, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) traded higher on Monday in response to President-elect Donald Trump&#8217;s plans to nominate Marty Makary to lead the Food and Drug Administration (FDA). Here&#8217;s <a href="https://www.benzinga.com/quote/HIMS/news">what you need to know.</a>
What To Know: Market optimism surrounding Makary's selection may have bolstered Hims &amp; Hers shares on Monday as investors anticipate that the nomination could bring favorable regulatory changes to the sector. Makary is a proponent of telehealth and an executive at Sesame, a company that connects consumers to physicians who can prescribe compounded weight-loss drugs.
Hunterbrook Capital released a <a href="https://hntrbrk.com/hims-follow-up/">bullish report</a> on Monday announcing a long position in Hims &amp; Hers Health, citing potential benefits from Makary&#8217;s leadership at the FDA. The report suggests that Makary's background and expertise could stabilize the compounded GLP-1 drug market, in which Hims &amp; Hers Health is actively involved.
The report also highlighted regulatory challenges Hims &amp; Hers Health has faced, including fluctuating FDA guidance on <a href="https://www.benzinga.com/news/earnings/24/11/41718402/whats-going-on-with-hims-hers-health-stock-monday">drug shortages</a> and scrutiny over its prescribing practices. Makary's history with telehealth and compounded drugs may signal a more supportive regulatory environment, driving investor optimism.
Hims has been expanding into the weight-loss drug market with compounded GLP-1 products, which are cheaper alternatives to branded drugs like Wegovy and Mounjaro. Regulatory clarity under Makary's potential leadership is seen as a positive development for the company.
HIMS Price Action: Hims &amp; Hers shares closed Monday up 23.9% at $31.39, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="532" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-1024x532.png" alt="" class="wp-image-664105" style="width:530px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-1024x532.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-300x156.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1-768x399.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25143843/HIMS-1.png 1468w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/markets/commodities/24/11/42172722/gold-down-over-3-rigetti-computing-shares-spike-higher">Gold Down Over 3%; Rigetti Computing Shares Spike Higher</a></li>
</ul>
Image: Mohamed Hassan from Pixabay

Movers

Hims & Hers Health, Inc. Class A Common Stock

HIMS

What's Going On With Hims & Hers Health Stock Monday?

HSAI

Hesai Group Expects Q4 Net Revenues To Approach $100M

Agora Expects Q4 Total Revenues To Be $34M - $36M, Also Expects Significant Improvement In Net Income / (Loss)

Hesai Q3 Adj EPS $(0.05) Misses $(0.02) Estimate, Sales $76.87M Beat $69.82M Estimate

For NBC, big balloons mean a bigger budget.
What Happened: The Macy's Thanksgiving Day Parade, known for its extravagant performances and cartoon character floats, is getting pricier. 
Since 1953, the peacock-branded network has aired the iconic turkey-day tradition. And, according to <a href="https://www.wsj.com/business/media/nbc-ready-to-pay-triple-to-gobble-up-thanksgiving-parade-broadcast-rights-e18fd95f?mod=hp_lead_pos5">The Wall Street Journal</a>, NBC is considering a $60-million agreement — triple the current $20 million rate — to secure those rights through the next decade. 
See Also: <a href="https://www.benzinga.com/news/retail-sales/24/11/42170721/thanksgiving-dinner-gobbles-up-19-more-cash-this-year-many-holiday-hosts-already-regret-their-decision">Thanksgiving Dinner Gobbles Up 19% More Cash This Year, Many Holiday Hosts &#8216;Already Regret Their Decision&#8217;</a>
So why the hefty price? Consider the appeal of live events in a streaming-dominated world. 
Comcast Corp.-owned (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMCSA#NASDAQ">CMCSA</a>) NBC and other traditional forms of TV are struggling to keep audiences after the whole cord-cutting trend. Marquee moments like parades, football games, boxing matches and awards shows are now popping up streaming services.
For NBC, the bet is that Peacock streaming customers will tune into the Nov. 28 crowd-pleaser, which is expected to feature celebrity appearances and live Broadway performances. 
Walt Disney Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIS#NYSE">DIS</a>) can relate. The Burbank, California-based conglomerate shelled out a 20% premium to swipe the Grammy Awards from Paramount Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARA#NASDAQ">PARA</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PARAA#NASDAQ">PARAA</a>), which had been airing it on CBS.
Why It Matters: The value of a live audience is as buoyant as a giant Snoopy balloon.
Nearly 30 million viewers tuned in to watch last year's parade, and this Thursday morning promises another spectacle of at least 11 marching bands, 28 clown crews, 22 balloons and 33 floats.
As for performers, viewers can expect a lineup of famous faces, including Charli D'Amelio, original &#8220;Wicked&#8221; star Idina Menzel, &#8220;Tonight Show&#8221; host Jimmy Fallon with The Roots, Coco Jones, Liza Colón-Zayas, The Temptations, T-Pain and the New York Liberty.
The route stretches 2.5 miles. It begins at 77th Street and Central Park West and winds its way down to Macy's Herald Square, the flagship store of Macy&#8217;s Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/M#NYSE">M</a>).
For those in New York City eager to preview the parade prep, the balloon inflation event happens Wednesday, Nov. 27, on the Upper West Side — a chance to get up close and personal with the towering inflatable icons.
Per <a href="https://www.usatoday.com/story/entertainment/tv/2024/11/21/macys-thanksgiving-day-parade-2024/76454992007/">USA Today</a>, this year&#8217;s event will debut new balloons, including Minnie Mouse, the Extraordinary Noorah and Gabby from Gabby&#8217;s Dollhouse.
Now Read:
<ul>
<li><a href="https://www.benzinga.com/24/11/42162655/macy-falls-as-preliminary-q3-highlights-mixed-performance-and-154-million-expense-concealment">Macy&#8217;s Delays Q3 Earnings Report Amid Investigation Over $154M Accounting Scandal; Stock Dips</a></li>
</ul>
Photo: Shutterstock

Entertainment

Events

Media

CMCSA

PARA

PARAA

Peacock Pays Up: Macy's Thanksgiving Parade Costs Set To Balloon For Content-Hungry NBC

Faraday Future plans to announce the date and detailed plan for the stock ticker symbol change in January 2025.
 &nbsp;

FFIE

Faraday Future Plans To Change its Stock Ticker Symbol From 'FFIE' To 'FFAI' In Early 2025

Agora Q3 EPADS $(0.26) Down From $(0.23) YoY, Sales $31.6M Down From $35.0M YoY

Offerings

State Street Plans Issuance Of $2.25B Of Senior Debt By Its Principal Banking Subsidiary, State Street Bank And Trust Company

IPOs

CGTL

Creative Global Technology Plans Pricing Of Its IPO Of 1.25M Ordinary Shares At $4.00 Per Share For Total Gross Proceeds Of $5M; To Commence Trading On November 26, Under The Ticker Symbol 'CGTL'

Eastman Kodak Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KODK#NYSE">KODK</a>) shares closed Monday&#8217;s session up more than 18% after the company announced plans to terminate its U.S. pension program. Here&#8217;s <a href="https://www.benzinga.com/quote/KODK/news">what you need to know.</a>
What To Know: In a new regulatory filing, Kodak said the Kodak Retirement Income Plan Trust entered into a purchase and sale agreement with Mastercard Foundation in which Mastercard will purchase certain private equity ownership interests and other illiquid assets. 
Kodak will sell the illiquid assets with a value of $764.4 million for a purchase price of $550.6 million in cash. Additional buyers will acquire $87.3 million in assets.
According to <a href="https://www.wsj.com/articles/kodak-prepares-to-terminate-u-s-pension-book-gain-of-more-than-500-million-d0cfb621?mod=lead_feature_below_a_pos3">The Wall Street Journal</a>, Kodak&#8217;s pension plan is overfunded, with $3.5 billion in assets and $2.3 billion in liabilities. The termination process will involve selling illiquid assets, settling liabilities and replacing the plan with a new retirement program. 
The termination is expected to result in a cash gain of $530 million to $585 million after taxes. Kodak plans to use these proceeds to reduce its $460 million in long-term debt, which includes a 12.5% term loan. Under its credit agreement, the company must reduce its debt balance to $200 million with proceeds of this size.
This move is aimed at improving Kodak's financial health, reducing interest expenses and investing in core business areas like pharmaceutical chemicals. The process is expected to take over a year and plan participants will retain the full value of their benefits through annuities or lump-sum payouts.
Kodak closed its latest quarter with $214 million in cash after reporting a quarterly profit of $18 million.
KODK Price Action: Eastman Kodak shares closed Monday at $6.24 after gaining 18.4% during regular trading hours, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a>
<figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1727794380964569"><img loading="lazy" decoding="async" width="1024" height="542" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-1024x542.png" alt="" class="wp-image-664229" style="width:483px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-1024x542.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-300x159.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK-768x407.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/11/25161042/KODK.png 1464w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/11/42174446/streaming-vinyl-propel-music-copyright-value-to-45-5-billion">Streaming, Vinyl Propel Music Copyright Value To $45.5 Billion</a></li>
</ul>
Photo: <a href="https://pixabay.com/users/jbooba-23039065/?utm_source=link-attribution&amp;utm_medium=referral&amp;utm_campaign=image&amp;utm_content=7452562">Gregor Mima</a> from Pixabay.

KODK

Kodak Stock Is Trading At 52-Week Highs: What's Going On?

Tim Draper, a prominent venture capitalist and cryptocurrency enthusiast, has made Bitcoin price predictions since 2014.
That year, Draper predicted Bitcoin to be $10,000 by the end of 2017. Despite skepticism, his forecast proved accurate, as Bitcoin hit $10,000 in November 2017 during its dramatic bull run.
In 2018, Draper forecast Bitcoin to reach $250,000 by the end of 2022. This bold prediction was not fully realized, though Bitcoin did reach an all-time high of approximately $69,000 in November 2021.
When Bitcoin failed to hit the target price in 2018, Draper extended the timeline to mid-2023. The futurist and investor based this target price on mass adoption, particularly by women and retail investors.
Draper said in an interview with Benzinga: "My first prediction was in 2014 when Bitcoin was at $180. I said that it would be $10,000 in three years. Sure enough, by the end of 2017, Bitcoin hit $10,000. Since then, I have not been as prescient. I thought Bitcoin would hit $250,000 by 2022! I think I am going to be three years off.&#8221; Draper added: &#8220;I think we can chalk those three years up to a weak government that regulated rather than encouraged new technologies. Our new government is more encouraging."
Since the U.S. presidential election in November, the crypto world has been celebrating with a decidedly more bullish outlook. Though many tokens have seen significant gains, including Ethereum (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/eth/usd">ETH</a>) and Solana (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/sol/usd">SOL</a>), Bitcoin has taken center stage, reaching a record high of $99,000 on Nov. 21, the second all-time high of the month.
Benzinga asked Draper what his prediction was for Bitcoin with the end of 2024 rapidly approaching and he responded: "This is just the beginning! If you are asking about price prediction, I would say about Bitcoin will reach about $120,000 by end of year."
Benzinga asked Draper what drives his future forecasts for Bitcoin, he pointed to the superiority of the cryptocurrency over traditional fiat and long-term trends in usage.
"It is a long-term trend. Bitcoin is just better technology than using banks and governments as the trusted third party. It is transparent, global, open, keeps perfect records, etcetera. It will make the world wealthier. When retailers (for currency) and governments (for taxes) realize that Bitcoin will save them money on each transaction, then there will be a great incentive for everyone to use Bitcoin."
When asked for his prognostication for 2025, Draper said he is holding out for the $250,000 level and cited the proposed U.S. Bitcoin reserve as a contributing factor.
"Assuming a standard supply and demand curve, if there is a big buyer like that, the price will continue to rise. I think 2025 is the year Bitcoin will finally hit my mark of $250,000," Draper noted.
See Also: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42165734/bitcoin-etfs-registered-record-312-billion-net-inflows-last-week">Bitcoin ETFs Registered Record $3.12 Billion Net Inflows Last Week</a>
<h1 class="wp-block-heading">MicroStrategy Leads the Bitcoin Charge</h1>
Michael Saylor, co-founder of MicroStrategy, <a href="https://x.com/saylor/status/1861033309934862601">tweeted today</a><a href="https://x.com/saylor/status/1861033309934862601" target="_blank" rel="noopener"> </a>that the company acquired $5.4 billion in Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>), the single biggest purchase of the world's leading decentralized digital currency.
In the tweet, Saylor stated, "MicroStrategy has acquired 55,500 BTC for ~$5.4 billion at ~$97,862 per #bitcoin and has achieved BTC Yield of 35.2% QTD and 59.3% YTD. As of 11/24/2024, we hodl 386,700 $BTC acquired for ~$21.9 billion at ~$56,761 per bitcoin. $MSTR"
This is after the news that the company is making $500 million a day with its Bitcoin holdings, which Saylor said have appreciated by $5.4 billion over the past two weeks. Saylor predicted Bitcoin could reach $13 million by 2045, which would elevate its market cap to $250 trillion. 
<h1 class="wp-block-heading">Optimism Among Web3 Leaders</h1>
Nathan Berkley, CEO of Muhdo Health Limited, a health technology company specializing in DNA and epigenetic testing which incorporates cryptocurrency into its operations, has a bullish outlook on Bitcoin and independently concurs with Draper's forecast.
"I think we could see Bitcoin hit $120,000. With U.S. sentiment being positive to this market now, and understanding Web3 can have real impact, it's a great time to be in the space," Berkley noted.
Lisa Loud, executive director of Secret Network Foundation, a blockchain platform designed to enable privacy-preserving decentralized applications, said: "The Bitcoin of today is not the Bitcoin of 2020: we have a broader finance interest, politics, and uncertain regulatory changes. A conservative estimate would say it will end in the range of $92,000-115,000, but if we get a large opt-in from mainstream, we could blow this estimate out of the water."
Read Next: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/42173367/shiba-inu-burn-rate-soars-487-in-a-day-what-is-going-on"> • Shiba Inu Burn Rate Soars 487% In A Day: What Is Going On?</a>
Photo: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Exclusives

Trading Ideas

$BTC

$ETH

$SOL

$USDT

$XRP

EXCLUSIVE: Tim Draper Predicts Bitcoin To Reach $120K By End Of 2024, $250K In 2025

The Q4 earnings report for Blue Bird (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLBD#NASDAQ">BLBD</a>) was released on Monday, November 25, 2024 at 04:00 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Blue Bird missed estimated earnings by -16.0%, reporting an EPS of $0.77 versus an estimate of $0.92.
Revenue was up $47.25 million from the same period last year.
<h3>Performance in Previous Earnings</h3>
During the previous quarter, the company beat on EPS by $0.4, leading to a 0.0% increase share price change the next day.
Here's a look at Blue Bird's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.51</td>
<td>0.48</td>
<td>0.37</td>
<td>0.48</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.91</td>
<td>0.89</td>
<td>0.91</td>
<td>0.66</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>328.60M</td>
<td>298.41M</td>
<td>275.13M</td>
<td>290.11M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>333.37M</td>
<td>345.92M</td>
<td>317.66M</td>
<td>302.96M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Blue Bird <a href="https://www.benzinga.com/quote/BLBD/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BLBD

Earnings Summary: Blue Bird Q4

Enanta Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ENTA#NASDAQ">ENTA</a>) released its Q4 earnings on Monday, November 25, 2024 at 04:01 PM.
Here's what's important from the earnings announcement.
<h3>Earnings</h3>
Enanta Pharma beat estimated earnings by 4.0%, reporting an EPS of $-1.36 versus an estimate of $-1.41.
Revenue was down $4.33 million from the same period last year.
<h3>Earnings History Overview</h3>
Last quarter the company beat on EPS by $0.38 which was followed by a 1.0% increase in the share price the next day.
Here's a look at Enanta Pharma's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-1.45</td>
<td>-1.33</td>
<td>-1.19</td>
<td>-2</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-1.07</td>
<td>-1.47</td>
<td>-1.58</td>
<td>-1.33</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>17.18M</td>
<td>16.52M</td>
<td>21.28M</td>
<td>17.50M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>17.97M</td>
<td>17.05M</td>
<td>18.00M</td>
<td>18.93M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Enanta Pharma <a href="https://www.benzinga.com/quote/ENTA/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ENTA

Enanta Pharma Earnings Analysis: Q4 Recap

The Q4 earnings report for Central Garden &amp; Pet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CENT#NASDAQ">CENT</a>) was released on Monday, November 25, 2024 at 04:02 PM.
Here's what investors need to know about the latest announcement.
<h3>Earnings</h3>
Central Garden &amp; Pet beat estimated earnings by 10.0%, reporting an EPS of $-0.18 versus an estimate of $-0.2.
Revenue was down $80.66 million from the same period last year.
<h3>Previous Earnings Records</h3>
The company beat on EPS by $0.11 in the last quarter, resulting in a 6.0% increase share price change the following day.
Here's a look at Central Garden &amp; Pet's past performance:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
<th>Q4 2023</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>1.21</td>
<td>0.80</td>
<td>-0.14</td>
<td>0.06</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>1.32</td>
<td>0.99</td>
<td>0.01</td>
<td>0.08</td>
</tr>
<tr>
<td>Revenue Estimate</td>
<td>1.00B</td>
<td>887.42M</td>
<td>619.95M</td>
<td>735.32M</td>
</tr>
<tr>
<td>Revenue Actual</td>
<td>996.35M</td>
<td>900.09M</td>
<td>634.53M</td>
<td>750.15M</td>
</tr>
</tbody>
</table>

To track all earnings releases for Central Garden &amp; Pet <a href="https://www.benzinga.com/quote/CENT/earnings">visit their earnings calendar here.</a> 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

CENT

Central Garden & Pet: Q4 Earnings Insights

Leslie&#8217;s Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LESL#NASDAQ">LESL</a>) reported its fourth-quarter results after Monday's closing bell. Here's a look at the <a href="https://www.benzinga.com/pressreleases/24/11/g42174678/leslies-inc-announces-fourth-quarter-fiscal-2024-financial-results-provides-first-quarter-fiscal-2">details from the report. </a>
The Details: Leslie&#8217;s reported quarterly earnings of two cents per share which missed the analyst consensus estimate of 11 cents. Quarterly revenue came in at $397.9 million which missed the analyst consensus estimate of $405.19 million and is a decrease from sales of $432.37 million from the same period last year.
For the fiscal year 2024: 
<ul>
<li>Comparable sales decreased 8.8%. Non-comparable sales including acquisitions and new stores contributed $7.9 million for the year.</li>
<li>Gross profit decreased 13% to $476.8 million compared to $548.2 million in the prior year.</li>
<li>Gross margin decreased to 35.8% from 37.8% in the prior year period. </li>
<li>Operating income was $57.1 million compared to $102.2 million in the prior year.</li>
</ul>
Read Next: <a href="https://www.benzinga.com/trading-ideas/movers/24/11/41949068/bitcoin-could-reach-1-million-by-2037-economist-says-buy-of-a-lifetime-opportunity">Bitcoin Could Reach $1 Million By 2037, Economist Says: &#8216;Buy Of A Lifetime&#8217; Opportunity</a>
&#8220;Our fourth quarter results were in line with our revised expectations on the top-line, and we saw strong performance in our Pro segment with some continued softness in store traffic and larger-ticket and discretionary categories. Profitability was affected by deleverage from the sales decline and a one-time contract item, though we have remained disciplined on SG&amp;A expenses,&#8221; said Jason McDonell, CEO of Leslie&#8217;s. 
Outlook: Leslie&#8217;s expects first-quarter sales of between $169 million and $176 million and gross profit of $45 million to $48 million. 
LESL Price Action: According to <a href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw">Benzinga Pro</a>, Leslie's shares are down 18.80% after-hours at $2.85 after gaining 10% during Monday&#8217;s regular trading session.
Read More:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/general/biotech/24/11/41822473/trumps-potential-health-czar-robert-f-kennedy-jr-rattles-vaccine-stocks-shoot-first-reaction">Trump&#8217;s Potential &#8216;Health Czar&#8217; Robert F. Kennedy Jr. Rattles Vaccine Stocks: &#8216;Shoot First Reaction&#8217;</a></li>
</ul>
Photo: Oleg Gamulinskii from Pixabay

LESL

Leslie's Stock Drops After Q4 Results: Here's Why

SPIR

Spire Global Says Selected By LatConnect60 To Provide Global Navigation Satellite System Reflectometry Data And Soil Moisture Insights

Oncternal Therapeutics Q2 2024 Earnings Preview

Oncternal Therapeutics GAAP EPS of -$2.89 beats by $0.14, revenue of $0.8M beats by $0.64M

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Oncternal Therapeutics (NASDAQ:<a href="https://investorplace.com/stock-quotes/onct-stock-quote/">ONCT</a>) just reported results for the second quarter of 2024.<ul><li>Oncternal Therapeutics reported earnings per share of -$2.89. This was above the analyst estimate for EPS of -$3.10.</li><li>The company reported revenue of $801,000.</li><li>This was 233.75% better than the analyst estimate for revenue of $240,000.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul>The post <a href="https://investorplace.com/earning-results/2024/08/onct-stock-earnings-oncternal-therapeutics-for-q2-of-2024/">ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

ONCT Stock Earnings: Oncternal Therapeutics Beats EPS, Beats Revenue for Q2 2024

Oncternal Therapeutics, Inc. (ONCT) Q2 2024 Earnings Call Transcript

Oncternal plunges on portfolio shakeup

Oncternal Therapeutics ( ($ONCT) ) has shared an announcement. Oncternal Therapeutics, Inc. is reducing its workforce by 37%, approximately 10 empl...

Oncternal Therapeutics Restructures Amid Clinical Setbacks

These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include:&nbsp...

Biotech Alert: Searches spiking for these stocks today

Oncternal Therapeutics (ONCT) has disclosed a new risk, in the Employment / Personnel category. Oncternal Therapeutics faces potential risks associ...

Oncternal Therapeutics Faces Workforce Reduction Challenges: Potential Risks and Implications

Oncternal Therapeutics ( ($ONCT) ) has provided an update. Oncternal Therapeutics, Inc. is undergoing a significant workforce reduction, effective ...

Oncternal Therapeutics Announces Workforce Reduction and Executive Changes

Oncternal Therapeutics ( ($ONCT) ) has released its Q3 earnings. Here is a breakdown of the information Oncternal Therapeutics presented to its inv...

Oncternal Therapeutics Reports Q3 2024 Earnings

ALLK

APVO

CNSP

CYCC

GNPX

IMUX

MBIO

ONCT

SYRS

Press Releases

Oncternal Therapeutics Reports Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

Oncternal Therapeutics to Provide Business Update and Report First Quarter 2024 Financial Results

Oncternal Therapeutics Provides Business Update and Announces First Quarter 2024 Financial Results

Health Care

Oncternal Announces Enrollment Completed and Dosing Initiated for Fifth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics to Present in JonesTrading Healthcare Summit

Oncternal Announces Enrollment Completed and Dosing Initiated for Sixth Dose Cohort of Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

Oncternal Therapeutics to Provide Business Update and Report Second Quarter 2024 Financial Results

Oncternal Therapeutics Provides Business Update and Announces Second Quarter 2024 Financial Results

General

Oncternal Therapeutics Announces Termination of its Clinical Studies and Exploration of Strategic Alternatives

Oncternal Therapeutics Announces Updated Safety and Efficacy Data for Phase 1/2 Study of ONCT-534 for the Treatment of R/R Metastatic Castration-Resistant Prostate Cancer

AquaBounty Technologies, Inc. - Common Stock

AquaBounty Techs

Anitra

Bone Biologics

Bio-Path Hldgs

Dogwood Therapeutics, Inc. - Common Stock

Dogwood Therapeutics

Lipella Pharmaceuticals Inc. - Common Stock

Lipella Pharmaceuticals

Lixte Biotechnology Holdings, Inc. - Common Stock

Lixte Biotechnology

Matinas Biopharma Holdings, Inc. Common Stock

Matinas BioPharma Hldgs

NuCana

Oragenics

Palisade Bio

Phio Pharmaceuticals Corp. - Common Stock

Phio Pharma

Qualigen Therapeutics, Inc. - Common Stock

Qualigen Therapeutics

Quoin Pharmaceuticals, Ltd. - American Depositary Shares

Quoin Pharmaceuticals

Revelation Biosciences, Inc. - Common Stock

Revelation Biosciences

Scinai Immunotherapeutics Ltd. - American Depositary Shares

Scinai Immunotherapeutics

Scorpius Holdings

Shuttle Pharmaceuticals Holdings, Inc. - common stock

Shuttle Pharmaceuticals

SILO Pharma

Synaptogenix

Sonnet BioTherapeutics Holdings, Inc. - Common Stock

Sonnet BioTherapeutics

Alaunos Therapeutics, Inc. - Common Stock

Alaunos Therapeutics

Tharimmune

Theriva Biologics

ZyVersa Therapeutics, Inc. - Common Stock

Comments

Oncternal Therapeutics

Intérêt court

Oncternal Therapeutics (NASDAQ:ONCT) Stock, Rapport sur les intérêts à découvert

Les gens regardent aussi

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL